SK Biopharm to Operate Independent Booth for Second Consecutive Year at BIO USA... Showcasing AI-Based Drug Development

Partnering with Global Pharmaceutical Companies and Investors
Introducing Company-wide AI Utilization Strategies

SK Biopharm announced on the 16th that it will participate in the 2026 Biotechnology Innovation Organization International Convention (BIO USA), which will be held in San Diego, USA, from June 22 to 25. The company will seek collaboration opportunities through partnering meetings with global pharmaceutical companies and investors, and will showcase its artificial intelligence (AI) strategies at its booth.

Front view of SK Biopharm booth at BIO USA 2026. SK Biopharm

BIO USA is the world’s largest bio industry event, organized by the Biotechnology Innovation Organization (BIO). This year, more than 20,000 pharmaceutical and bio industry professionals from over 76 countries are expected to attend to share major industry trends and innovative technologies.

For the second consecutive year, SK Biopharm will operate an independent booth, which is located in the main exhibition area, the ‘Digital Health and AI Zone’. BIO USA established this zone last year to make digital health and AI technologies a major industry agenda, concentrating booths of related companies in a key location of the venue. This year, the event is again structured to provide insights into the direction and expansion potential of AI utilization across the pharmaceutical and bio industry.

During this year’s BIO USA, SK Biopharm plans to discuss potential collaborations in a wide range of areas, including research and development, business development, and new modalities, through one-on-one partnering meetings with global pharmaceutical and bio companies as well as investors. In particular, the company will continue to seek opportunities to expand its business in the global market, while also focusing on deepening understanding of its drug development capabilities and next-generation growth engines.

At its booth, SK Biopharm will introduce its company-wide AI utilization strategy under the slogan ‘SK, AI for Every Patient’, highlighting: ▲ AI-based novel drug discovery, ▲ digital transformation of research and development and work operations, and ▲ patient-centric platforms. Based on these initiatives, the company aims to reinforce AI-driven research and development and data-centric decision-making systems to enhance productivity in drug development and work execution, and to further develop these capabilities as the foundation for future growth.

SK Biopharm plans to continuously advance its predictive models and data analysis systems based on its proprietary AI platform, while gradually expanding the scope of AI application to all aspects of drug development and company operations, including research planning, candidate substance design and analysis, development strategy establishment, and operational optimization. In addition, the company is building a work environment where employees collaborate with AI agents, and in the long term, aims to evolve into a system where multiple AI agents support research and development processes and work flows, ultimately increasing the efficiency of drug development and the accuracy of decision-making.

Lee Donghun, CEO of SK Biopharm, stated, "This year’s BIO USA is an important opportunity to seek new collaboration prospects through partnering with the global pharmaceutical and bio industry, and to introduce both SK Biopharm’s R&D capabilities and AI strategies. Going forward, we will continue to expand our global collaboration base, strengthen our global competitiveness by leveraging AI and data to improve productivity and execution in drug development, and provide therapeutic solutions to more patients in need."

This content was produced with the assistance of AI translation services.